DEWITT STETTEN JR., M.D., Ph.D.
Because of the prominence of the hyperglucemia and the glucosuria as manifestations of diabetes mellitus, great reliance has been placed upon the correction of these abnormalities in the assessment of possible insulin substitutes. When a new agent comes to light which causes a lowering in the blood glucose concentration in normal subjects and in many diabetic patients, when this agent is effective upon oral administration and when this drug appears to be devoid of all important toxic side-reactions, it is inevitable that it be explored as a possible therapeutic agent. Such a drug, according to the clinical consensus, is 1-butyl-3-p-tolylsulfonylurea
STETTEN D. THE HYPOGLUCEMIC SULFONYLUREA DRUGS—AN INTERIM EVALUATION. Ann Intern Med. ;46:1005–1008. doi: 10.7326/0003-4819-46-5-1005
Download citation file:
Published: Ann Intern Med. 1957;46(5):1005-1008.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use